Navigation Links
Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
Date:3/4/2010

LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay Enterprises, Inc. (OTC Bulletin Board: CHYE) is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals will trade on the NASDAQ BB under the symbol CHYE.  "We have asked FINRA to change our symbol," said Don Wingerter, Ampio Pharmaceuticals' CEO, "and expect to be trading under our new symbol in less than thirty days."

"Ampio Pharmaceuticals' management has extensive experience in drug discovery and development, and has created a substantial pipeline of pharmaceuticals that address significant, unmet medical needs.  These pharmaceutical developments are in the category of so-called 'Repurposed Drugs,' pharmaceuticals previously shown to be safe and effective treatments in distinct therapeutic categories," said Mr. Wingerter.  "By entering the public space we will have access to capital to advance our pipeline and a public forum to educate patients and showcase our commercialization activities."


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... PLAINS, N.Y. , May 22, 2013  The ... million to Valor Biotherapeutics, LLC, a joint ... of pre-clinical development, manufacturing, and a Phase I clinical ... the poor outcomes faced by many patients with indolent ... rituximab. Valor,s protein, IGN002, is a ...
(Date:5/22/2013)... CAESAREA, Israel , May 22, 2013 ... presented from the DEFLECT-I study demonstrates that Keystone Heart,s ... volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when ... Advisory Board announces consensus on the importance of preserving ... and need for cerebral protection during cardiovascular procedures to ...
(Date:5/22/2013)... -- For the 3% of the population that suffer from ... anxiety-inducing and disabling.  While more than half of these ... hyperhidrosis is a serious medical condition.  Finally, there is ... Dr. Bruce Katz , ... New York , is leading an ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 3New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 4Is There Finally A Way To Stop Severe Excessive Sweating? 2
... May 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader ... Citi Investment Research,s 2010 Global Health Care Conference on Thursday, May 27, ... Hotel. , , , ... the presentation will be available on the "Investors & Media" section of the ...
... Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) ... Small Business Technology Transfer Research (STTR) grant from the ... grant was awarded to support the Company,s program to ... combat Staphylococcus aureus ( S. aureus ...
Cached Medicine Technology:Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference 2Sorrento Therapeutics Awarded NIH Grant for MRSA Program 2Sorrento Therapeutics Awarded NIH Grant for MRSA Program 3Sorrento Therapeutics Awarded NIH Grant for MRSA Program 4
(Date:5/23/2013)... FL (PRWEB) May 23, 2013 ... regenerative medicine company focused on the commercialization of ... and regeneration, today announced that the Company and ... million grant, for which AxoGen’s portion is approximately ... administrated by the U.S. Department of Defense (DoD) ...
(Date:5/23/2013)... 2013 Hile Design LLC is pleased ... awarded a Silver Creative Award at the Summit International ... entry was for its “Open Doors” animation promoting Scio ... in the 2013 District 6 ADDY Awards for the ... Creative Award recognizes and celebrates the creative achievements of ...
(Date:5/23/2013)... Utah (PRWEB) May 23, 2013 Registered ... R.D., published an article today on Tatalou.com offering helpful ... vacation. , The article, titled “ How to Stay ... important to carry hand sanitizer, when it’s safe to ... out for seafood, the importance of staying hydrated and ...
(Date:5/23/2013)... OH and Durham, NC (PRWEB) May 23, 2013 ... and commercialization firm that funds and develops innovative ... Deep Brain Innovations, LLC (DBI). DBI will ... optimize deep brain stimulation (DBS) therapy for patients ... is effective in treating Parkinson’s disease and generates ...
(Date:5/23/2013)... Consortium, Ltd., issued the following statement today on ... Reform of chemical safety legislation will succeed only ... Ensuring the safety and appropriate use of chemicals ... Toxic Substances Control Act is a critical opportunity ... transforming toxicity testing "from a system based on ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 2Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 3Health News:How to Stay Healthy While Traveling 2Health News:NDI Launches Deep Brain Innovations, LLC 2Health News:NDI Launches Deep Brain Innovations, LLC 3
... global research,organization, announced that it has appointed new staff ... Resourcing Solutions,division. Maria Sanchez Garcia will lead the group ... whilst Hannah King joins our United,Kingdom team to focus ... very pleased to help in the continued growth of ...
... deal demonstrates commitment to dermatology and innovation, ... Stiefel Laboratories, Inc.,the world,s largest independent pharmaceutical ... has completed its previously announced,acquisition of Princeton, ... of the acquisition, all remaining outstanding shares ...
... Call and Webcast Scheduled for August 7, 2008 ... Aug. 6 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... quarter of fiscal,year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...
... ... Diluted FAD ... Second Quarter Investments $250 Million, NEWPORT BEACH, Calif., ... operations,and investment activity for the second quarter and the six months ended,June 30, 2008., ...
... put themselves at increased risk for second malignancies , , ... British adults who survived childhood cancers currently smoke, while ... in their lives, a new study reports. , ... cancer have a greater chance of developing cardiovascular disease, ...
... Aug. 6 AMN Healthcare Services,Inc. (NYSE: AHS ... leader in all of its business segments today reported ... quarter last year and a 7%,increase from last quarter. ... Nurse & Allied, Locum Tenens and,Physician Permanent Placement, experienced ...
Cached Medicine News:Health News:Chiltern's Resourcing Solutions Division Appoints New Managers to Spain and the United Kingdom 2Health News:Stiefel Laboratories Completes Acquisition of Barrier Therapeutics 2Health News:Stiefel Laboratories Completes Acquisition of Barrier Therapeutics 3Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 2Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 3Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 4Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 5Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 6Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 7Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 8Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 9Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 10Health News:The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance 11Health News:NHP Reports Second Quarter 2008 Earnings 2Health News:NHP Reports Second Quarter 2008 Earnings 3Health News:NHP Reports Second Quarter 2008 Earnings 4Health News:NHP Reports Second Quarter 2008 Earnings 5Health News:NHP Reports Second Quarter 2008 Earnings 6Health News:NHP Reports Second Quarter 2008 Earnings 7Health News:NHP Reports Second Quarter 2008 Earnings 8Health News:NHP Reports Second Quarter 2008 Earnings 9Health News:NHP Reports Second Quarter 2008 Earnings 10Health News:NHP Reports Second Quarter 2008 Earnings 11Health News:NHP Reports Second Quarter 2008 Earnings 12Health News:NHP Reports Second Quarter 2008 Earnings 13Health News:NHP Reports Second Quarter 2008 Earnings 14Health News:One-Fifth of British Childhood Cancer Survivors Smoke 2Health News:AMN Healthcare Reports Second Quarter 2008 Results 2Health News:AMN Healthcare Reports Second Quarter 2008 Results 3Health News:AMN Healthcare Reports Second Quarter 2008 Results 4Health News:AMN Healthcare Reports Second Quarter 2008 Results 5Health News:AMN Healthcare Reports Second Quarter 2008 Results 6Health News:AMN Healthcare Reports Second Quarter 2008 Results 7Health News:AMN Healthcare Reports Second Quarter 2008 Results 8Health News:AMN Healthcare Reports Second Quarter 2008 Results 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: